Archive · 3 Oct 2025
FDA Approves Eli Lilly's Inluriyo for Advanced Breast Cancer
The US government has approved a new medicine called Inluriyo to help women with a specific type of advanced breast cancer.
This medicine is for those whose cancer has gotten worse after previous hormone therapy.
It comes in a pill you take once a day.
In trials, Inluriyo slowed down the cancer's growth by about 38%.
Some patients taking the drug experienced better survival rates.
Possible side effects include feeling tired, having an upset stomach, or changes in blood levels.
The medicine will be available in the US soon.
The FDA approved Inluriyo, an oral medication for advanced breast cancer.
Inluriyo is for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer patients.
The drug is intended for patients whose disease has progressed after at least one hormone therapy course.
Inluriyo lowered the risk of cancer progression or death by 38% in trials.
Common side effects include fatigue, diarrhea, and changes in cholesterol and blood levels.
- Who
- US FDA and Eli Lilly
- What
- Approved Inluriyo, a new oral medication for advanced breast cancer.
- When
- September 25
- Where
- United States
- Why
- To treat advanced breast cancer and reduce progression risk.
- Drug Name
- Inluriyo (imlunestrant)
- Manufacturer
- Eli Lilly
- Approval Date
- September 25
- Target Cancer Types
- ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
- Progression Risk Reduction
- 38%
- Side Effects
- Fatigue, diarrhea, nausea, constipation, musculoskeletal pain, cholesterol issues, blood count changes
